{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:04:28Z","timestamp":1791353068871,"version":"4.3.1"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T00:00:00Z","timestamp":1403827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate ixekizumab, an anti\u2013interleukin\u201017A (anti\u2013IL\u201017A) monoclonal antibody, in 2 populations of rheumatoid arthritis (RA) patients: biologics\u2010naive patients and patients with an inadequate response to tumor necrosis factor (TNF) inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase II, randomized, double\u2010blind study, placebo or ixekizumab was administered subcutaneously to 260 biologics\u2010naive patients and 188 patients with an inadequate response to TNF inhibitors at weeks 0, 1, 2, 4, 6, 8, and 10 with concomitant disease\u2010modifying antirheumatic drugs. The primary objective was to determine the dose\u2010response relationship of ixekizumab as measured by the proportion of biologics\u2010naive patients meeting the American College of Rheumatology 20% improvement criteria (ACR20) at week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using a logistic regression model defined a priori, a statistically significant dose\u2010response relationship as measured by ACR20 response rates at week 12 was detected in biologics\u2010naive patients (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.031). For patients with an inadequate response to TNF inhibitors, ACR20 responses at week 12 were significantly better with ixekizumab than placebo (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Decreases in the Disease Activity Score in 28 joints using the C\u2010reactive protein level (DAS28\u2010CRP), Clinical Disease Activity Index (CDAI), and CRP level from baseline were observed at week 12 in the ixekizumab groups in both populations (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05 versus placebo). Onset of action was rapid in some dose groups in both populations, with improvements in the ACR20, DAS28\u2010CRP, CRP levels, and CDAI observed by day 3 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Adverse events occurred with similar frequencies overall in the ixekizumab and placebo groups. Infections were more frequent with ixekizumab than placebo (biologics\u2010naive 25% versus 19%; inadequate responders to TNF inhibitors 27% versus 25%). No mycobacterial or invasive fungal infections were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ixekizumab improved RA signs and symptoms in RA patients who were either naive to biologics treatment or had an inadequate response to TNF inhibitors. The safety profile was similar to that of other biologic agents, with no unexpected safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.38617","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T10:51:32Z","timestamp":1394621492000},"page":"1693-1704","source":"Crossref","is-referenced-by-count":197,"title":["A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti\u2013Interleukin\u201017 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors"],"prefix":"10.1002","volume":"66","author":[{"given":"Mark C.","family":"Genovese","sequence":"first","affiliation":[{"name":"Stanford University Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Greenwald","sequence":"additional","affiliation":[{"name":"Desert Medical Advances Palm Desert California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul\u2010Soo","family":"Cho","sequence":"additional","affiliation":[{"name":"Catholic University of Korea and St. Mary's Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Berman","sequence":"additional","affiliation":[{"name":"Centro M\u00e9dico Privado de Reumatolog\u00eda Tucuman Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Cameron","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benichou","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Braun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010Yves","family":"Berclaz","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-3285-4.10023-3"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2010.517815"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20001"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27334"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050524"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis criteria that include simplified joint counts","volume":"41","author":"Gestel AM","year":"1998","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_13_1","first-page":"2576","article-title":"Activity indices in rheumatoid arthritis","volume":"27","author":"Villaverde V","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_8_14_1","first-page":"892","article-title":"Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials","volume":"28","author":"Lassere MN","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1787"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_8_18_1","first-page":"789","article-title":"The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales","volume":"9","author":"Fries JF","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_8_19_1","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. August 9 2006. URL:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201601"},{"key":"e_1_2_8_22_1","first-page":"S362","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, multiple\u2010dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"64","author":"Pavelka K","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23383"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013052"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090074"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.633509"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20221"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.02.014"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh512"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074773"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.01.004"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3431"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201024"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38617","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:45:06Z","timestamp":1759934706000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,27]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/art.38617"],"URL":"https:\/\/doi.org\/10.1002\/art.38617","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,27]]}}}